Hepatitis C drugs not being accessed by thousands of Australians with the disease
By Lexi Metherell
The trend means the Government is at risk of missing its target to eradicate hepatitis C and of spending far more than necessary on the treatments.
Hepatitis Australia said fewer than half as many people were accessing the direct acting antivirals as they were immediately after they were first listed on the Pharmaceutical Benefits Scheme (PBS) in March 2016.
The trend means the Government is at risk of missing its target to eradicate hepatitis C and of spending far more than necessary on the treatments.
Hepatitis Australia said fewer than half as many people were accessing the direct acting antivirals as they were immediately after they were first listed on the Pharmaceutical Benefits Scheme (PBS) in March 2016.
No comments:
Post a Comment